Ipsen

Ipsen is a biopharmaceutical business with its headquarters in Paris, France. The company focuses on developing breakthrough treatments in the fields of oncology, rare disease, and neuroscience. Regarding sales in the cancer sector, Ipsen is among the top 15 biopharmaceutical companies in the world.

Ipsen was established in 1929 by Henri Beaufour, and the company currently has over 5000 people across the globe. Ipsen's pharmaceuticals have been granted registration in over one hundred countries, and the company has a direct commercial presence in over thirty of those nations. Ipsen is comprised of 3 pharmaceutical research centers and 4 worldwide R&D hubs located all over the world.

Ipsen has been run by the same family for the past ninety years, and the company is currently listed on the Euronext Paris stock exchange as a component of the SBF 120 index (2005). Two of the Beaufour family members, Anne Beaufour and Henri Beaufour, serve on the company's board of directors. The Beaufour family holds 57% of the company's shares and 73% of its voting rights.

Founded: 1929

Headquarters: Boulogne-Billancourt, France

Website: https://www.ipsen.com/